~(18)F-FDG摄取程度、Ki-67表达与DLBCL分期之间的相关性讨论

目的探讨弥漫大B细胞淋巴瘤~(18)F标记的氟代脱氧葡萄糖(~(18)F-FDG)摄取程度、核抗原Ki-67表达与临床分期之间的关系。方法回顾性分析我院70例弥漫大B细胞淋巴瘤患者的病历资料,所有患者均经病理及免疫组化结果确诊,治疗前均常规行~(18)F-FDG PET/CT扫描。结果弥漫大B细胞淋巴瘤患者病灶~(18)F-FDG平均摄取值(SUVave)与Ki-67指数呈显著正相关,相关系数r为0.843,P0.001;Ki-67指数与淋巴瘤分期显著相关(P0.001),且Ki-67指数越高,临床分期越趋向晚期;~(18)F-FDG平均摄取值与淋巴瘤分期无相关性。弥漫大B细胞淋巴瘤患者Ki-67表达水平与肿瘤分期、最大肿瘤直径及血LDH水平有相关性(P0.05)。结论 Ki-67与PET/CT在反映弥漫大B细胞淋巴瘤患者细胞增殖情况及病灶的侵袭程度等方面有着紧密的联系。     

子宫肌瘤~(18)F-FDG PET/CT显像高代谢机制的初步探讨

目的探讨18F-2-氟-2脱氧-D-葡萄糖(18F-FDG)正电子发射体层摄影术(PET)/CT显像上子宫肌瘤的高代谢表现及机制。资料与方法回顾性分析2007年7月至2010年8月接受PET/CT检查的受检女性(共1785例)的PET/CT图像,以18F-FDG摄取高于肝脏作为代谢增高的标准,子宫出现高代谢病灶者共147例,其中9例经病理证实为子宫肌瘤。结果 9例子宫肌瘤表现为18F-FDG代谢增高的受检者年龄34~57岁,平均46岁,子宫肌瘤18F-FDG代谢的18F-FDF最大标准摄取值(SUVmax)为4.4~20.4。绝经前期子宫肌瘤的18F-FDG摄取多见,且SUVmax高于绝经后期。绝经前期子宫肌瘤的18F-FDG摄取与月经周期无明显相关,但增殖期子宫肌瘤的SUVmax低于分泌期。结论子宫肌瘤可以表现为18F-FDG代谢增高,不应一概视为恶性。认识子宫肌瘤的高代谢表现有助于减少假阳性,提高诊断准确性。     

PET/CT显像淋巴瘤病灶18F-FDG摄取程度与肿瘤增殖性抗原Ki-67相关性研究

目的:通过对比50例不同病理亚型的淋巴瘤肿瘤增殖性抗原Ki-67表达水平与"F-FDG PET显像病灶"F-FDG浓聚程度来探讨两者之间相关性.方法:收集50例经病理及免疫组化证实的淋巴瘤病例,每个病例均有酶标肿瘤增殖性抗原Ki-67染色免疫组化报告,病理检查前或后常规行PET/CT检查.病理分型均采用WHO分类标准,并对非霍奇金淋巴瘤例按WF分类标准对其进行大小细胞类型归类.Ki-67酶标染色结果统一采用分级方法:核抗原染色阳性细胞百分数为0～5%,表示为微弱阳性(+/-);百分数为5%～20%,表示为弱阳性(+);百分数为20%～50%,表示为中阳性(++);百分数大于50%,表示为强阳性(+++).PET/CT影像上,病灶18F-FDG摄取程度采用半定量分析方法,计算出病灶平均标准化摄取值SUV(SUVave).利用统计软件(SPSS13.0)计算不同病理亚型的病灶18F-FDG摄取值(以x±s表示),并对大、小细胞类型淋巴瘤的FDG摄取值差异显著性行t检验;对所有病灶Ki-67表达水平与18F-FDG摄取程度两者之间采用Spearman方法进行相关性分析.结果:大细胞来源的淋巴瘤18F-FDG摄取值远高于小细胞来源的淋巴瘤18F-FDG摄取值,特别是B系大小细胞不同类型淋巴瘤.其18F-FDG摄取值差异性更显著;Ki-67表达水平同结性与结外病灶18F-FDG摄取值两者存在显著相关性,r值分别为0.750和0.843.结论:反映肿瘤增殖活性的Ki-67与淋巴瘤病灶18F-FDG摄取程度有明显关系,Ki-67表达程度较高的大细胞性进展性淋巴瘤,其病灶18F-FDG摄取值很高,而Ki-67表达程度较低的小细胞性低度恶性淋巴瘤,其18F-FDG摄取值较低.     

孤立性肺结核球的~(18)F-FDGPET/CT影像学表现

目的：探讨孤立性肺结核球（PTM）的18F-脱氧葡萄糖（FDG）PET/CT影像学表现。方法：回顾性分析23例经病理或临床证实为孤立性PTM患者的18F-FDG PET/CT影像学资料,所有患者均经注射18F-FDG 60min后行螺旋CT平扫和PET显像,分别对PTM进行形态学分析和标准摄取值（SUV）半定量分析。结果：23例病例中,CT平扫显示孤立性PTM直径为1.11~5.10 cm,平均2.48 cm;结节边缘光滑者16例,结节内有空洞者4例、钙化者3例;同时合并纵隔、肺门或腋窝淋巴结增大者6例。本组患者中17例发生18F-FDG摄取,其中11例表现为肺内结节局限性18F-FDG浓聚,6例表现为肺内结节和增大淋巴结18F-FDG浓聚,平均SUVmax为4.01±1.89;12例18F-FDG摄取阳性的患者经抗结核治疗后病灶缩小;6例未发生18F-FDG摄取的患者,经CT随访12个月病灶无明显变化。结论：18F-FDG PET/CT对孤立性PTM的诊断具有重要价值,确诊有赖于穿刺活检或手术病理。     

皮下脂膜炎样T细胞淋巴瘤18F-FDGPET/CT影像分析并文献复习(附4例报道)

目的 总结皮下脂膜炎样T细胞淋巴瘤（SPTCL）的18F-FDG PET/CT影像学特点,探讨18F-FDG PET/CT在SPTCL中的应用价值。 方法 回顾性分析4例经病理证实的SPTCL患者的影像学表现,观察病灶的形态、分布范围、代谢信息,结合其临床、病理特点复习相关文献。 结果 4例患者的18F-FDG PET/CT影像学表现:病灶形态不规则,密度增高,相应部位18F-FDG摄取增高。病变累及范围广泛,面颈（2例）、躯干（4例）、四肢（4例）、腹膜和盆腔脂肪组织（2例）均可受累。半定量分析结果:皮下脂肪病灶最大标准化摄取值为3.5~14.6。 结论 SPTCL病变分布广泛,18F-FDG摄取差异较大,但18F-FDG PET/CT显像有利于整体评估SPTCL患者病情,在疗效监测方面具有重要作用。      

骨淋巴瘤的~(18)F-FDG PET/CT表现

目的探讨骨淋巴瘤18F-FDG PET/CT显像的影像学特点。方法搜集经病理组织学证实的骨淋巴瘤患者35例,其中原发性骨淋巴瘤4例,继发性骨淋巴瘤31例,分析其18F-FDG PET/CT表现。结果 4例原发性骨淋巴瘤均为非霍奇金淋巴瘤,单骨发病,表现为骨质破坏伴软组织肿块,放射性摄取增高,SUVmax 7.9~17.9。31例继发性骨淋巴瘤,霍奇金淋巴瘤5例,非霍奇金淋巴瘤26例,单骨发病2例,多骨发病29例,骨质密度异常表现多样,具体分为:(1)骨质破坏型20例,表现为不同程度溶骨性骨质破坏,邻近可伴或不伴有软组织肿块,放射性摄取不同程度增高,SUVmax 2.5~15.0;(2)骨质硬化型3例,以骨质硬化为主,病变区域骨质密度高于正常骨骼,不伴有邻近的软组织肿块影;放射性摄取无异常增高或轻度增高,SUVmax 1.0~5.6;(3)骨髓浸润型8例,全身骨髓弥漫性放射性摄取增高,SUVmax 1.7~9.8,无骨质密度异常。结论骨淋巴瘤18F-FDG PET/CT影像学表现有一定的特征性,分析其表现,对原发性和继发性骨淋巴瘤的诊断、鉴别诊断有重要的临床价值。     

三阴性乳腺癌的PET/CT检查时~(18)F-FDG摄取和预后因素之间的相关性

正摘要目的本研究旨在观察~(18)F-氟代脱氧葡萄糖(~(18)F-FDG)的摄取和三阴性乳腺癌(TNBC)的预后因素之间是否存在相关性。方法 2009年1月—2013年12月间,103例三阴性乳腺癌病人(平均年龄,50.6岁;病灶平均直径2.6 cm,最小1.0 cm,最大6.5 cm)为了明确分期情况进行了~(18)F-FDG PET/CT检查。评估PET/CT检查的最大标准化吸收值(SUV_(max))、肿瘤大小、淋巴结转移情况、病理分级、增殖指数Ki-67、肿瘤抑制因子p53以及"基底样细胞"制造者(表皮生长因子受体和K5/6)这些预后因素之间的关系。结果 103例     

~(18)F-FDG PET/CT显像在肺部恶性肿瘤治疗中的疗效评价

目的探讨~(18)F-FDG PET/CT显像观察98例胸部恶性肿瘤治疗后疗效的作用。方法 ~(18)F-FDG PET/CT显像检查了98例手术+放化疗、放化疗和氩氦刀3类治疗后的胸部恶性肿瘤患者,分析3种治疗方法的疗效;并对比同机CT病灶分布的特征,分析与~(18)F-FDG PET显像的异同。结果受检患者98例中阳性87例,阴性11例,其中手术+放化疗44例(阳性34例,阴性10例);放化疗组15例(阳性14例,阴性1例);氩氦刀组39例(阳性39例)。各治疗组之间~(18)FFDG PET/CT显示的治疗后残存病灶数量差异有显著意义(X~2=24.40,P0.001)。~(18)F-FDG PET显示病灶130个,病灶最大横径2.2~9.4cm,平均(5.20±1.73)cm;同机CT显示病灶132个,最大横径1.0~10.6cm,平均(4.48±2.19)cm,~(18)F-FDG PET与同机CT显示的病灶大小基本一致,差异无显著意义(t=0.079,P0.05),二者正相关性关系(r=0.85,P0.01)。但是PET反应的是残留恶性组织的活性而CT仅是解剖改变。~(18)F-FDG PET病灶的T/NT比值1.3~26.07,平均6.32±5.48。结论 ~(18)F-FDG PET/CT在观察胸部恶性肿瘤疗效中有较大临床价值。     

结核病18F-FDG PET图像表现的多样性

目的总结结核病18F-脱氧葡萄糖(FDG) PET显像的影像学特征.方法回顾性分析26例结核病患者的18F-FDG PET图像,其中21例由组织病理学检查结果证实,余5例据临床资料诊断.所有患者在注射18F-FDG 60～90 min后进行衰减校正全身PET显像.其中14例患者同时行早期(40～65 min)和延迟(1.5～2.5 h)双时相检查.图像判读包括目测法和标准摄取值(SUV)半定量分析.双时相显像计算SUV变化率[ΔSUV(%)].结果 26例结核病患者中22例可见18F-FDG摄取,肺结核摄取18F-FDG有4种基本类型肺结节局限性18F-FDG浓聚(9例);肺内病灶同时伴有肺门或纵隔淋巴结浓聚(5例);肺伴有锁骨上和(或)腹腔淋巴结异常浓聚(3例);广泛胸膜异常浓聚(2例).平均SUVmax为3.64±2.58(1.4～7.6 ).延迟相SUV与早期相比较随时间延长而增加[(34.62±7.25)%].3例肺外结核18F-FDG PET显像呈阳性.4例陈旧性肺结核患者在CT所示结节部位未见18F-FDG摄取.结论结核病18F-FDG摄取可作为结核活动性的一个标志,其18F-FDG PET表现呈多样性.阳性18F-FDG摄取在肺部结节良恶性鉴别诊断时应慎重,特别是多发高代谢病灶背景不清晰时.背景不清晰的病灶结合结核菌素试验阳性,应考虑结核可能.     

结核病18F-FDG PET图像表现的多样性

目的总结结核病18F-脱氧葡萄糖(FDG) PET显像的影像学特征.方法回顾性分析26例结核病患者的18F-FDG PET图像,其中21例由组织病理学检查结果证实,余5例据临床资料诊断.所有患者在注射18F-FDG 60～90 min后进行衰减校正全身PET显像.其中14例患者同时行早期(40～65 min)和延迟(1.5～2.5 h)双时相检查.图像判读包括目测法和标准摄取值(SUV)半定量分析.双时相显像计算SUV变化率[ΔSUV(%)].结果 26例结核病患者中22例可见18F-FDG摄取,肺结核摄取18F-FDG有4种基本类型:肺结节局限性18F-FDG浓聚(9例);肺内病灶同时伴有肺门或纵隔淋巴结浓聚(5例);肺伴有锁骨上和(或)腹腔淋巴结异常浓聚(3例);广泛胸膜异常浓聚(2例).平均SUVmax为3.64±2.58(1.4～7.6 ).延迟相SUV与早期相比较随时间延长而增加[(34.62±7.25)%].3例肺外结核18F-FDG PET显像呈阳性.4例陈旧性肺结核患者在CT所示结节部位未见18F-FDG摄取.结论结核病18F-FDG摄取可作为结核活动性的一个标志,其18F-FDG PET表现呈多样性.阳性18F-FDG摄取在肺部结节良恶性鉴别诊断时应慎重,特别是多发高代谢病灶背景不清晰时.背景不清晰的病灶结合结核菌素试验阳性,应考虑结核可能.     

The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients

Fully diagnostic positron emission tomography (PET)/CT scans acquired during oral and intravenous contrast can be provided to patients and referring physicians in a single imaging session. Although FDG uptake varies, most low-grade lymphomas exhibit sufficient FDG avidity to also be staged reliably with FDG PET/CT. PET/CT imaging is more accurate for lymphoma staging than PET or CT alone and has substantial impact on patient management. This accurate whole-body glucose metabolic survey should serve as the baseline for subsequent treatment response evaluations. PET/CT has evolved to become the modality of choice for staging of nodal and extranodal lymphoma, for assessing therapeutic response, and for establishing patient prognosis.     

False-Positive FDG PET Uptake−the Role of PET/CT

Positron emission tomography (PET) is a powerful molecular imaging technique for the human body-imaging applications currently available. As altered glucose metabolism is characteristic for many malignancies, FDG-PET is mostly used in oncology for staging and therapy control. Although PET is a sensitive tool for detecting malignancy, FDG uptake is not tumor specific. It can also be seen in healthy tissue or in benign disease as inflammation or posttraumatic repair and could be mistaken for cancer. The experienced nuclear medicine physician mostly manages to differentiate malignant from non-malignant FDG uptake, but some findings may remain ambiguous. In these cases, the difficulties in differentiating physiologic variants or benign causes of FDG uptake from tumor tissue can often be overcome by combined PET and CT (PET/CT) as anatomic information is added to the metabolic data. Thus, PET/CT improves the diagnostic accuracy compared to PET alone and helps to avoid unnecessary surgery/therapy. However, PET/CT involves other sources of artifacts that may occur when using CT for attenuation correction of PET or by patient motion caused by respiration or bowel movements.     

FDG avidity and PET/CT patterns in primary gastric lymphoma

PURPOSE: The use of 18F-fluoro-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in primary gastric lymphoma (PGL) is challenging due to physiologic FDG activity in the stomach and variability in the degree of uptake in various histologic subtypes. This study assesses FDG avidity and PET/CT patterns in newly diagnosed PGL. METHODS: Sixty-two PET/CT studies of newly diagnosed PGL were reviewed (24 low-grade mucosa-associated lymphoid tissue [MALT], 38 aggressive non-Hodgkin's lymphoma [AGNHL]). FDG avidity, patterns (focal/diffuse), and intensity (visually vs. the liver and SUVmax) were assessed and compared to 27 controls. Gastric CT abnormalities and extragastric sites were recorded. RESULTS: Gastric FDG uptake was found in 55/62 (89%) PGL (71% MALT vs. 100% AGNHL, p < 0.001) and 63% controls. A diffuse pattern was found in 60% PGL (76% MALT vs. 53% AGNHL, p = NS) and 47% controls. FDG uptake higher than liver was found in 82% PGL (58% MALT vs. 97% AGNHL, p < 0.05) and 63% controls. SUVmax in FDG-avid PGLs was 15.3 +/- 11.7 (5.4 +/- 2.9 MALT vs. 19.7 +/- 11.5 AGNHL, p < 0.001) and 4.6 +/- 1.4 in controls. CT abnormalities were found in 79% PGL (thickening, n = 49; ulcerations, n = 22). Extra-gastric FDG-avid sites were seen in none of MALT, but 61% of AGNHL (nodal, n = 18; nodal and extranodal, n = 5). CONCLUSIONS: FDG avidity was present in 89% of PGLs, including all patients with AGNHL but only 71% of MALT. FDG uptake can be differentiated, in particular in AGNHL-PGL, from physiologic tracer activity by intensity but not by pattern. Extragastric foci on PET and structural CT abnormalities are additional parameters that can improve PET/CT assessment of PGL. Defining FDG avidity and PET/CT patterns in AGNHL and a subgroup of MALT-PGL before treatment may be important for further monitoring therapy response.     

Abdominal Mesh Implant Showing FDG Uptake on PET/CT

F-18 fluorodeoxyglucose (FDG) uptake by a mesh implant might be caused by a foreign body granulomatous reaction with inflammation and fibrosis, which can be demonstrated by positron emission tomography/computed tomography (PET/CT). A 71-year-old man underwent F-18 FDG PET/CT for the follow-up evaluation after an operation for colonic adenocarcinoma. On PET/CT imaging, there was a rectangular-shaped FDG uptake (maximal standardized uptake value, maxSUV: 3.4) in the anterior abdominal wall. On the review of the medical records, the patient had a history of herniorrhapy for the reinforcement of the abdominal wall 2 months previously, using a mesh implant consisting of polytetrafluoroethylene (Teflon). We report a case of FDG uptake associated with surgical procedures including mesh implant on F-18 FDG PET/CT.     

F-FDG PET and PET/CT in Burkitt's lymphoma

Objective

To explore the value of ¹⁸F fluorodeoxy-glucose (FDG) positron emission tomography (PET) in Burkitt's lymphoma.

Methods

All Burkitt's lymphoma patients referred for FDG PET or FDG PET/computed tomography (CT) exams at our institution from June 2003 to June 2006 were included. Selected patients were followed and clinical information was reviewed retrospectively. Results from FDG PET-PET/CT, as blindly reviewed by a consensus of two experienced readers, were compared with the status of the disease as determined by other laboratory, clinical and imaging exams and clinical follow-up. FDG PET-PET/CT results were classified as true positive or negative and false positive or negative. The degree of FDG uptake in the positive lesions was semiquantified as maximum standard uptake value (SUVmax).

Results

Fifty-seven FDG PET-PET/CT exams were done in 15 patients. Seven exams were done for initial staging, 8 during and 14 after the completion of therapy, and 28 for disease surveillance. For nodal disease FDG PET-PET/CT was true positive in 8, true negative in 47 and false positive in 2 exams (sensitivity 100%, specificity 96%). For extranodal disease FDG PET-PET/CT was true positive in 6, true negative in 48 and false positive in 3 exams (sensitivity 100%, specificity 94%). The mean SUVmax for the positive nodal lesions was 15.7 (range 6.9-21.7, median 18.5) and for extranodal lesions was 14.2 (range 6.2-24.3, median 12.4).

Conclusions

FDG PET-PET/CT is sensitive for the detection of viable disease in Burkitt's lymphoma. Affected areas demonstrated high degree of uptake that was reversible upon successful implementation of treatment.     

Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT

The aim of this study was to investigate the correlations between ¹⁸F-FDG uptake by bone marrow and various hematological parameters.

Forty-eight patients who underwent FDG-PET/CT studies and also received hematological examinations within 5 days before or after the PET study were included in this study. All patients had not received chemotherapy. FDG uptake by bone marrow was measured as a standardized uptake value (SUV) on three-dimensional PET/CT fusion images, and the uptake ratio (UR) of the SUV of bone marrow to the SUV of longitudinal dorsal muscle was calculated. The correlations between the SUV and the UR of bone marrow and various hematological parameters were evaluated.

Bone marrow FDG uptake was strongly correlated with the white blood cell counts but was not significantly correlated with the red blood cell and platelet counts. The neutrophil count was significantly correlated with bone marrow FDG uptake but the lymphocyte count was not.

FDG uptake by bone marrow was specifically correlated with the neutrophil count, suggesting that the FDG uptake by bone marrow reflects marrow metabolism that is mainly regulated by granulocyte progenitors and stimulated by endogenous hematopoietic growth factors. They may also be helpful in interpreting PET images, especially for diagnosing bone marrow involvement by malignancy.     

Scalene muscle uptake: a potential pitfall in head and neck PET/CT

Purpose To describe increased 2-deoxy-2-[¹⁸F] fluoro-D-glucose (FDG) uptake in the scalene muscles in a large population of patients referred for evaluation with FDG positron emission tomography/computed tomography (PET/CT) imaging. Methods The study met criteria for institutional review board exemption. FDG PET/CT images from 410 patients (179 males; mean age 56.8 years, range 6-88) were retrospectively reviewed for the presence or absence of FDG uptake in the neck that corresponded to the scalene muscles on the concurrent CT scan. Medical records were reviewed and data including age, sex, smoking history, reason for referral, and history of obstructive airways disease, thoracotomy, and thoracic radiation were recorded and evaluated. Results One hundred and forty-seven of the 410 scans (36%) demonstrated increased FDG uptake on PET that corresponded to the scalene muscles on the CT scan. The uptake was most often bilateral, symmetrical, and linear (n = 117). Other patterns of scalene muscle uptake included unilateral and linear uptake (n = 27) and unilateral and focal uptake (n = 3). Scalene muscle uptake was more common in patients referred for evaluation of lung carcinomas compared to other types of tumors (52% vs. 32%, p = 0.05). Conclusion Linear FDG uptake in scalene muscles is a commonly seen pattern on PET/CT. This finding should be recognized as a distinct entity and not misinterpreted on transverse images as metastatic disease.     

Peritoneal Lymphomatosis Imaged by F-18 FDG PET/CT

Peritoneal lymphomatosis is uncommon, but when encountered is associated with aggressive histological subtypes of high-grade lymphoma, such as small-cell, large-cell, mixed large and small cell, non-cleaved, lymphoblastic Burkitt-like, and diffuse large B cell lymphomas. The CT findings of peritoneal lymphomatosis are linear or nodular peritoneal thickening, retroperitoneal lymphadenopathy, omental and mesenteric involvement with streak-like infiltrations or a bulky mass, bowel wall thickening, hepatosplenomegaly, and ascites. The authors report the first FDG PET/CT images of diffuse large B-cell lymphoma of small bowel origin associated with peritoneal lymphomatosis in a 69-year-old man. The lesions demonstrated intense FDG uptake in PET/CT images.     

Non-malignant FDG uptake in infradiaphragmatic adipose tissue: a new site of physiological tracer biodistribution characterised by PET/CT

The purpose of this study was to characterise a benign pattern of infradiaphragmatic ¹⁸F-fluorodeoxyglucose (FDG) uptake in cancer patients using PET/CT. Infradiaphragmatic foci of FDG uptake, localised by PET/CT in regions of normal fat tissues, were demonstrated, in conjunction with fatty uptake in the neck and shoulders, in 9 of 1,241 (0.7%) patients. The imaging and clinical characteristics of this pattern and its possible clinical significance were assessed. PET/CT precisely localised infradiaphragmatic fat uptake (IDFU) within normal retroperitoneal fatty tissue of the perirenal space (nine patients) and in the paracolic or parahepatic space (four patients). Perirenal uptake was bilateral in five patients and focal in six. Paracolic and parahepatic uptake was bilateral in three patients and linear in all four patients. There was no evidence of malignancy at any of the sites during a follow-up period of 9–21 months. IDFU was significantly more prevalent in young patients assessed for monitoring response to therapy, and was always associated with the benign supradiaphragmatic uptake pattern, although its prevalence was significantly lower. There were no significant differences between the clinical characteristics of these two patterns of benign fatty FDG uptake. It is concluded that PET/CT allows for precise identification of increased FDG uptake in abdominal fatty tissue and further exclusion of disease at such sites. This benign uptake may represent increased glucose consumption in activated brown adipose tissue, similar to the mechanism suggested for supradiaphragmatic uptake. Recognition of this benign IDFU pattern is important for correct interpretation of abdominal PET findings in cancer patients.     

Inverse correlation between tumor perfusion and glucose uptake in human head and neck tumors

RATIONALE AND OBJECTIVES: We sought to determine the relationship between tumor blood flow and glucose uptake in head and neck tumors using perfusion computed tomography (PCT) and fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET). MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained for this study. Sixteen patients (mean age, 67 years; age range, 36-89 years) who had known or suspected head and neck tumors (15 malignant tumors and one schwannoma) underwent PCT and FDG PET examinations. Tumor area was measured on conventional CT images. The PCT data were postprocessed using maximum slope method analysis, and standardized uptake value (SUV) was measured on FDG PET. RESULTS: Mean arterial perfusion of the tumors was 61.56 mL/min/100 mL (range 22.17-102.7 mL/min/100 mL), and mean FDG SUV was 7.48 (range 2.74-17.1). A significant negative correlation between arterial perfusion and FDG SUV was found for malignant tumors (r = -0.538, P = .04, n = 15). CONCLUSION: There was an inverse relationship between arterial perfusion and glucose uptake of head and neck malignant tumors, suggesting that the malignant tumors may depend on anaerobic glycolysis.